Stay updated on Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.

Latest updates to the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study details with an access-denied notice. The error screen includes the standard site chrome and footer, indicating the content is not reachable in this view.SummaryDifference24%

- Check11 days agoChange DetectedThe page revision label has been updated from v3.6.6 to v3.7.0, indicating a new revision of the page rather than a substantive change to the study details.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedEnrollment updated to 89 participants, and key dates updated from estimated to actual: primary completion on 2026-06-10 and study completion on 2027-08-26, with the latest update posted on 2026-08-28.SummaryDifference0.3%

- Check54 days agoChange DetectedUPMC Hillman Cancer Center was added as a Pittsburgh study site, and University of Pittsburgh Cancer Institute (UPCI) was removed from the listed locations.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4. This reflects a new revision release of the Study Details page, likely including minor fixes or tweaks to metadata or content.SummaryDifference0.0%

- Check89 days agoChange DetectedThe page now displays revision v3.6.3, replacing the previous revision v3.6.1. This indicates a version update to the page, likely reflecting minor edits or corrections rather than substantive changes to study information.SummaryDifference0.0%

Stay in the know with updates to Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Olaparib & Atezolizumab in BRCA+ Breast Cancer Clinical Trial page.